-
'Blind spots': drone alert lays bare Lithuania poor shelter access
-
French UFC fighter Gane blocking out politics before White House bout
-
England aim to erase Ashes scars against New Zealand
-
50 years after Olympic glory, Comaneci's homecoming sparks hope of new path to perfection
-
'No hiding' as Haiti thrash New Zealand in pre-World Cup friendly
-
Military seeks prison time for Indonesian soldiers in acid attack
-
'Animalistic horror': Russia puts war art on display
-
German alleged rape victim battles time limit on abuse cases
-
As crises balloon, so do EU nations' deficits
-
Japan's samurai spirit still burns in cooler conditions
-
Solomons PM says to review secretive security pact with China
-
Oil prices rise on Iran peace worries, stocks build on tech rally
-
Sabalenka homes in on French Open semis
-
Trump signs AI order giving government access to powerful models
-
Pope to mark centenary of death of 'God's architect' Antoni Gaudi
-
Migrant journeys in focus ahead of pope visit to Spain's Canaries
-
Flood warnings as storm moves towards Tokyo
-
Scotland's Tartan Army to bring 'the party' on World Cup return
-
Thousands protest Jared Kushner-linked resort project in Albania
-
EU to unveil plan to wean itself off US, Asia tech
-
Solomons PM says to review security pact with China
-
Will SpaceX IPO make Elon Musk a trillionaire?
-
By the power of great skills: Nicholas Galitzine on He-Man transformation
-
'20 minutes of terror': AI boosts US voice impersonation scams
-
Before SpaceX goes public, a scramble to get on bandwagon
-
One of our own: San Antonio embraces 'Wemby' ahead of NBA Finals
-
Tanzania president visits Russia as Western ties fray
-
Keiko Fujimori: Peru's biggest political loser eyes election win
-
Protesting teachers in Mexico topple player statues days before World Cup
-
Scientists find yeast in ancient Iceman's guts -- and make bread
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - June 03
-
MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting
-
No.1 Korda, No.2 Jeeno chase US Women's Open title
-
Trump admin abandons $1.8 bn fund to compensate supporters
-
Canada and Mexico tell US they want free trade deal renewed
-
David Beckham to get star on Hollywood Walk of Fame
-
Turkey raps Kanye West for offending 'spiritual sensitivities'
-
Zverev powers into French Open semis as Fonseca run ends
-
Foreign companies take flight from US-sanctioned Cuba
-
Knicks, Brunson in awe of 'unbelievable' Wembanyama
-
Mensik tames Fonseca to reach French Open semi-finals
-
'I can't breathe': clashes erupt after UK police handcuff dying student
-
England launch World Cup build-up in steamy Florida
-
France lawmakers say state shares blame for West Indies pesticide scandal
-
'Crazy': Trump-Netanyahu relationship under growing strain
-
Ellis's best helps Australia shock Pakistan to level ODI series
-
Brunson says doubters only push Knicks to work harder
-
'I can't breathe': outrage, violence after UK police handcuff dying student
-
Zverev 'doesn't care' about French Open favourite tag
-
Israel, Hezbollah trade blows as diplomats meet in Washington
MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting
GENEVA, CH / ACCESS Newswire / June 3, 2026 / MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today published the invitation to its 2026 Annual General Meeting (AGM), which will be held on June 25, 2026, at 11:00 a.m. CEST in Geneva, Switzerland.
At the AGM, the Board of Directors will propose the re-election of the current Board members and the election of Brad Hollinger, Founder, Chairman and Chief Executive Officer of Vibra Healthcare, and Zach Henderson, Chief Executive Officer of MindMaze Therapeutics, as new members of the Board of Directors.
The agenda also includes the approval of the 2025 Annual Report and financial statements, the election of the members of the Nomination and Compensation Committee, the Independent Proxy and the statutory auditors, as well as votes on the compensation of the Board of Directors and the Executive Committee. Shareholders will also be asked to approve an increase in the Company's conditional share capital.
Further details on the proposals and the AGM invitation are available on the Company's website.
About MindMaze Therapeutics
MindMaze Therapeutics (SIX:MMTX) is a global leader in scalable, precision neurotherapeutics, dedicated to redefining the recovery trajectory for patients around the world. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy. The company's FDA-cleared and CE-marked products are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson's disease, and other neurological disorders. With an extensive library of rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine. For more information, visit www.mindmazetherapeutics.com.
Media & Investor Contacts
Investor Relations:
Jeremy Meinen, Chief Financial Officer
[email protected]
Media Inquiries:
VSC for MindMaze Therapeutics
[email protected]
DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE: MindMaze Therapeutics Holding SA
View the original press release on ACCESS Newswire
D.Moore--AMWN